Quality of life improvement at midterm follow-up after transcatheter aortic valve implantation

Abstract Background Transcatheter aortic valve implantation (TAVI) techniques have been presenting good procedural success and favorable clinical outcomes. However, optimal management of aortic valve disease in elderly patients depends on quality of life (QoL) improvement. In this study we aimed to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cardiology 2013-01, Vol.162 (2), p.117-122
Hauptverfasser: Gonçalves, Alexandra, Marcos-Alberca, Pedro, Almeria, Carlos, Feltes, Gisela, Hernández-Antolín, Rosa Ana, Rodríguez, Enrique, Rodrigo, José Luis, Cobiella, Javier, Maroto, Luis, Cardoso, José C. Silva, Macaya, Carlos, Zamorano, José Luis
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Transcatheter aortic valve implantation (TAVI) techniques have been presenting good procedural success and favorable clinical outcomes. However, optimal management of aortic valve disease in elderly patients depends on quality of life (QoL) improvement. In this study we aimed to evaluate changes in QoL in patients referred for TAVI. Methods and results Prospective analysis of 74 consecutive patients (34 male), aged 81.6 ± 8 years with symptomatic severe aortic valve stenosis (AS) ineligible for conventional aortic valve replacement, referred to TAVI in one tertiary center. For the assessment of QoL, the Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used before the procedure and at 6.5 months. The mortality was 9.5% at 30 days and 20.2% at 6.5 months follow-up. Fifty three (71.6%) patients completed MLHFQ at baseline and at follow-up. All patients showed good hemodynamic results and no signs of prosthesis dysfunction were observed on transthoracic echocardiography. The New York Heart Association (NYHA) class (2.9 ± 0.4 to 1.4 ± 0.7; p < 0.001), and the MLHFQ scores [overall (37.0 ± 14.7 vs. 14.4 ± 10.1; p < 0.001), physical dimension (23.2 ± 9.5 vs. 8.6 ± 5.9; p < 0.001) and emotional dimension (5.4 ± 4.2 vs. 2.6 ± 3.0; p < 0.001)] were significantly improved 6.5 months after TAVI. Patients with peripheral vascular disease (PVD) had an inferior improvement in QoL caused by a lower enhancement in physical dimension MLHFQ score (mean difference: − 17.0 ± 10.2 vs. − 10.1 ± 11.5; p = 0.036). Conclusion TAVI significantly improves symptoms and QoL in patients with severe AS and high surgical risk. Patients with PVD might be expected to have a less impressive improvement in QoL after TAVI.
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2011.05.050